Global Custom Market Research Reports Provider Company

phone

Graves Ophthalmopathy - Pipeline Review, H1 2018

  • Published Date: 12 Jun 2018
  • Number of Pages: 35
  • Category: Pharmaceuticals
  • Country: Global
Graves Ophthalmopathy - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Graves Ophthalmopathy - Pipeline Review, H1 2018, provides an overview of the Graves Ophthalmopathy (Ophthalmology) pipeline landscape.

Graves ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Gravesophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Graves Ophthalmopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Graves Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Graves Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves Ophthalmopathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Graves Ophthalmopathy - Overview
Graves Ophthalmopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Graves Ophthalmopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Graves Ophthalmopathy - Companies Involved in Therapeutics Development
Enceladus Pharmaceuticals BV
Genmab A/S
Novartis AG
Yuhan Corp
Graves Ophthalmopathy - Drug Profiles
pasireotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prednisolone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teprotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-BIO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-NCE3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Graves Ophthalmopathy - Dormant Projects
Graves Ophthalmopathy - Product Development Milestones
Featured News & Press Releases
Oct 25, 2017: Horizon Pharma Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease
Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Graves Ophthalmopathy, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Graves Ophthalmopathy - Pipeline by Enceladus Pharmaceuticals BV, H1 2018
Graves Ophthalmopathy - Pipeline by Genmab A/S, H1 2018
Graves Ophthalmopathy - Pipeline by Novartis AG, H1 2018
Graves Ophthalmopathy - Pipeline by Yuhan Corp, H1 2018
Graves Ophthalmopathy - Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products under Development for Graves Ophthalmopathy, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

General Data Protection Regulation (GDPR) in the Healthcare Industry: Implications for Healthcare - H1 2018 The EU voted to implement updated data protection laws in the form of the General Data

View Report

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview

View Report

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2018, provides

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports